News: Simtuzumab

We provide the latest news and info on Simtuzumab


Bidness ETC

Gilead's simtuzumab fails pancreatic cancer trial
PharmaTimes
The company has announced results from a Phase II study evaluating simtuzumab, an inhibitor of the lysyl oxidase-like-2 enzyme, in combination with current standard of care gemcitabine (Eli Lilly's Gemzar). The data show that the addition of simtuzumab ...
Gilead Down on Weak Simtuzumab Data and Sovaldi NewsZacks.com
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously ...MarketWatch
Gilead's simtuzumab fails Phase 2 trial (GILD)Seeking Alpha (registration)
StockWise Daily -Drug Discovery & Development
all 45 news articles »

Published on Monday 23rd of March 2015 01:25:56 PM Read more...


Gilead: Huge Long-Term Growth Potential Based On Philip Fisher's Ideals (GILD)
Seeking Alpha (registration)
A specific drug to note is Simtuzumab, a potential blockbuster treatment for various diseases such as colorectal cancer and myelofibrosis. Gilead is also constantly on the lookout for new acquisition/partnership deals. These deals are typically signed ...

and more »

Published on Monday 23rd of March 2015 01:25:56 PM Read more...


For advanced pancreatic cancer, simtuzumab not significantly more effective ...
Oncology Nurse Advisor
Gilead Sciences, Inc. has announced results from their phase 2 trial studying simtuzumab plus gemcitabine for the treatment of patients with previously untreated advanced pancreatic cancer. Researchers found that patients who received gemcitabine in ...

Published on Monday 23rd of March 2015 01:25:56 PM Read more...


Drug Discovery & Development

What Does Orphan Drug Approval For Gilead Sciences, Inc. (GILD)'s ...
InvestCorrectly
Gilead Sciences, Inc. (NASDAQ:GILD)'s monoclonal antibody Simtuzumab recently obtained orphan drug status as a treatment for a rare liver-related disorder – primary sclerosing cholangitis. The designation may provide Gilead increased patent protection ...
Gilead Sciences: A 'Logical' Deal That 'Fits Well'Barron's (blog)
Gilead Sciences Inc To Acquire Phenex's Liver-Disease ProgramBidness ETC
Gilead Sciences Just Received Orphan Drug Status For Liver TreatmentBenzinga

all 107 news articles »

Published on Monday 23rd of March 2015 01:25:56 PM Read more...


Should Gilead Acquire Puma Biotechnology?
Seeking Alpha (registration)
Finally, Martin noted that Simtuzumab and the anit-LOXL2 antibody is being evaluated for pancreatic and colorectal cancer. Regarding the pipeline, Gilead has Idealisib in stage III trials for frontline CLL and iNHL, and compounds in phase 2 trials for ...

and more »

Published on Monday 23rd of March 2015 01:25:56 PM Read more...


Gilead Sciences' (GILD) Management Presents at Cowen & Company 35th ...
Seeking Alpha (registration)
In addition to the ongoing developments in HIV and HCV, we have programs exploring a cure for hepatitis B and treatments for NASH with simtuzumab being our most advanced program for NASH at this point. We have also been busy building and acquiring ...

and more »

Published on Monday 23rd of March 2015 01:25:56 PM Read more...


This is Money

SMALL CAP SHARE TIPS: Abzena bucks the biotech trend as it generates ...
This is Money
The most advanced of these modified antibodies is simtuzumab, developed to treat liver fibrosis, scarring of the organ that can result in cirrhosis. Analysts believe the treatment may have blockbuster potential. If this is the case, even a low single ...
Abzena shares have 19% upside, research house calculatesProactive Investors UK

all 7 news articles »

Published on Monday 23rd of March 2015 01:25:56 PM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts